← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Neurogenetic Pharmaceuticals, Inc.
San Diego, CA
$6,106,360
Total funding
2
Grants
Funding over time
peak $1.4M · FY2011–17$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$6,106,360 · 2
By mechanism
U44$3,357,322 · 1
R01$2,749,038 · 1
Investigators at Neurogenetic Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$1,379,813
R01 · FY2015 · AG
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$1,093,421
R01 · FY2016 · AG
Pre-clinical development of NGP 555 for the prevention of AD$999,911
U44 · FY2013 · NS
Pre-clinical development of NGP 555 for the prevention of AD$999,681
U44 · FY2012 · NS
Pre-clinical development of NGP 555 for the prevention of AD$999,249
U44 · FY2014 · NS
Pre-clinical development of NGP 555 for the prevention of AD$288,481
U44 · FY2011 · NS
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$138,884
R01 · FY2016 · AG
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$136,920
R01 · FY2017 · AG
Pre-clinical development of NGP 555 for the prevention of AD$70,000
U44 · FY2014 · NS